IL10 and B-cell chronic lymphocytic leukemia: Both ibrutinib and ruxolitinib block IL-10 production by TLR-activated CLL cells but ruxolitinib prevents sustained transcription and translation of IL10 mRNA (Figures 2, 3) while ibrutinib blocks early transcription (Figure 5).